Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: October 16, 2013
Reporting Period: Single event date (October 16, 2013)
MediciNova, Inc. filed this report to disclose the entry into a new equity distribution agreement and the termination of a prior stock purchase agreement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or margin data. The following financial parameters relate specifically to the new equity distribution agreement:
- Maximum Offering Size: Up to $10 million in aggregate offering price.
- Commission Rate: 7% of gross proceeds paid to the sales agent (Macquarie Capital (USA) Inc.).
- Price Floor: Sales price per share cannot be less than the greater of $1.29 or the last available closing price on The NASDAQ Global Market.
- Issuance Limits: No single issuance notice may propose sales greater than the lower of $50,000 or 10% of the average daily traded value (5-day or 3-month).
Material Changes
The filing details two primary material changes effective October 16, 2013:
- New Agreement: Entered into an "at-the-market" equity distribution agreement with Macquarie Capital (USA) Inc. (MCUS) to sell common stock up to $10 million.
- Termination: Terminated the Common Stock Purchase Agreement dated August 20, 2012, with Aspire Capital Fund, LLC. The terminated agreement had allowed for the potential sale of up to $20 million in shares over a two-year term.
Guidance, Outlook, and Risks
Management Commentary: The Company is not obligated to make any sales under the new agreement and may terminate it at any time upon written notice. Sales are subject to the continued effectiveness of the Company's shelf registration statement on Form S-3 (declared effective December 3, 2012), though the Company makes no assurance regarding its continued effectiveness.
Risks and Contingencies:
- Sales are contingent on market conditions and the Company's issuance notices.
- The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
- Reliance on the shelf registration statement (File No. 333-185022) for the validity of the offering.
Investor Verification Checklist
- Verify the current status and effectiveness of the Company's Form S-3 shelf registration statement (File No. 333-185022).
- Review the full text of the Equity Distribution Agreement (Exhibit 10.1) for specific terms regarding indemnification and termination.
- Monitor future 8-K filings or press releases for actual issuance notices and sales volumes under the new agreement.
- Confirm the current trading price on The NASDAQ Global Market to assess the $1.29 price floor constraint.